HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Human Genome Sciences and its development partner GlaxoSmithKline are on track to initiate a Phase III study of LymphoStat-B for the treatment of systemic lupus erythematosus in 2006, HGS said.